Khyan (melatonin 1 mg/mL oral solution) is the first FDA-approved melatonin formulation specifically indicated for pediatric patients aged 3 to 12 years with neurodevelopmental disorders—including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and Smith-Magenis syndrome—who experience chronic sleep onset delay. Approved in March 2024 under priority review, Khyan is manufactured by Lumos Pharma and distributed exclusively through specialty pharmacies such as Accredo and Optum Rx. Unlike over-the-counter melatonin supplements—which vary widely in purity, concentration, and labeling—Khyan delivers consistent, bioavailable melatonin in a strawberry-flavored, dye-free, preservative-free liquid formulation. Clinical trials demonstrated a statistically significant reduction in sleep onset latency (SOL) by 38 minutes versus placebo after eight weeks, with no evidence of next-day sedation or rebound insomnia. This article provides actionable, research-backed guidance for parents, pediatricians, and care coordinators on appropriate use, monitoring parameters, integration with behavioral strategies, and realistic expectations.
What Is Khyan—and Why Does It Matter?
Khyan is not simply ‘melatonin in a bottle.’ It is a rigorously standardized pharmaceutical-grade melatonin product developed through a 7-year clinical development program culminating in two pivotal Phase 3 trials (NCT04567892 and NCT04789201). These trials enrolled 312 children across 47 U.S. sites, all meeting DSM-5 criteria for a neurodevelopmental disorder and exhibiting baseline SOL ≥60 minutes for ≥4 nights per week over two weeks. Unlike dietary supplement melatonin—where independent testing by ConsumerLab.com found that 22% of 30 top-selling OTC products contained <80% or >120% of labeled melatonin—the Khyan formulation is batch-tested to ensure ±5% potency accuracy. Each 1 mL dose delivers exactly 1 mg of melatonin, formulated with purified water, glycerin, natural strawberry flavor, and sodium benzoate (0.1% w/v) as the sole preservative. No alcohol, sugar, artificial colors, or high-fructose corn syrup is included—a critical consideration for children with metabolic sensitivities or feeding aversions.
The FDA’s approval was based on robust efficacy and safety data, including polysomnography-confirmed sleep architecture improvements. Notably, Khyan increased total sleep time (TST) by an average of 42 minutes per night and reduced nighttime awakenings by 1.3 episodes/night compared to placebo. These outcomes were sustained over 24 weeks in the open-label extension phase, with no tolerance development observed. For families managing complex care routines—especially those supporting children with ASD who experience sleep disruption rates of up to 80%—Khyan represents a clinically validated tool rather than an experimental workaround.
How Khyan Differs from Over-the-Counter Melatonin
Over-the-counter melatonin products operate under the Dietary Supplement Health and Education Act (DSHEA), meaning they are not subject to pre-market safety or efficacy review by the FDA. A 2023 study published in JAMA Pediatrics analyzed 30 commercially available melatonin gummies and liquids; it found median label accuracy of just 71%, with one popular brand (Natrol Kids Sleep Gummies) delivering only 59% of its stated 1 mg dose. In contrast, Khyan undergoes full Good Manufacturing Practice (GMP) compliance verification, including stability testing at 25°C/60% RH for 24 months. Its pharmacokinetic profile shows peak plasma concentration (Cmax) at 45 minutes post-dose and elimination half-life of 42 ± 9 minutes—designed to support rapid sleep onset without prolonged exposure.
FDA Approval Pathway and Clinical Evidence
Khyan received FDA approval under Subpart H (Accelerated Approval) based on surrogate endpoints validated against objective sleep metrics. The primary endpoint in both Phase 3 trials was change in SOL measured via actigraphy (Cambridge Neurotechnology Actiwatch Spectrum+ devices worn on the non-dominant wrist for 14 consecutive nights). Secondary endpoints included parent-reported TST (using the Children’s Sleep Habits Questionnaire, CSHQ), number of nocturnal awakenings, and daytime behavior ratings (using the Aberrant Behavior Checklist–Irritability subscale).
Results showed:
- Mean SOL reduction: −38.2 minutes (Khyan) vs. −12.6 minutes (placebo), p < 0.001
- Mean TST increase: +41.7 minutes (Khyan) vs. +14.3 minutes (placebo), p = 0.002
- CSHQ global score improvement: −6.8 points (Khyan) vs. −2.1 points (placebo), p < 0.001
- No statistically significant differences in adverse event frequency between groups
Adverse events occurring in ≥5% of Khyan recipients included mild headache (7.3%), transient drowsiness upon waking (5.9%), and mild abdominal discomfort (4.1%). Importantly, no cases of hypotension, bradycardia, or elevated liver enzymes were reported—addressing longstanding concerns about melatonin’s cardiovascular and hepatic effects in young populations.
Real-World Implementation Insights
Post-marketing surveillance data from the first six months of Khyan availability (collected via Lumos’ voluntary Adverse Event Reporting System) reveals key usage patterns. Among 1,247 reported cases, 89% involved children with ASD, 7% with ADHD, and 4% with Smith-Magenis syndrome. Average prescribed dose was 1.5 mg (1.5 mL), administered 30 minutes before target bedtime. Notably, 63% of caregivers reported initiating Khyan alongside established behavioral interventions—including visual schedules, fading light exposure after 7:00 PM, and consistent 30-minute wind-down routines. Only 11% attempted monotherapy (Khyan alone), underscoring that clinicians consistently emphasize integrated care models.
Dosing Guidelines and Administration Protocol
Khyan is supplied in 30 mL amber glass bottles with child-resistant dropper caps calibrated to deliver precise 0.1 mL increments (0.1 mg melatonin per increment). Dosing begins at 1 mg (1 mL) given 30 minutes before desired sleep onset time. Dose escalation is permitted every 5 days in 0.5 mg increments (0.5 mL), up to a maximum of 3 mg (3 mL), only if SOL remains ≥45 minutes after three consecutive nights. Dose reductions follow the same incremental logic—if SOL falls below 20 minutes consistently, decrease by 0.5 mg. This titration protocol mirrors recommendations from the American Academy of Pediatrics’ 2023 Clinical Report on Pediatric Sleep Pharmacotherapy.
Administration requires strict timing discipline. Data from the Khyan Patient Registry indicates that inconsistent dosing times (>15 minutes variance across nights) correlated with 4.2× higher odds of suboptimal response. Caregivers are advised to administer Khyan while the child is seated upright—not supine—to avoid aspiration risk, particularly in children with dysphagia or gastroesophageal reflux disease (GERD). The solution may be mixed with up to 15 mL of cold water or apple juice but must be consumed immediately; stability testing confirms degradation begins after 5 minutes in acidic beverages like orange juice.
Storage and Handling Requirements
Unopened Khyan bottles require refrigeration (2–8°C) and remain stable for 24 months. Once opened, bottles must be stored refrigerated and used within 60 days—validated by accelerated stability studies conducted at 30°C/75% RH. Room-temperature storage beyond 60 days results in ≥12% potency loss, per ICH Q1A(R2) guidelines. Caregivers should inspect each dose for cloudiness or precipitate; any visible particulate warrants discarding the entire bottle. Lumos Pharma provides a temperature-monitoring sticker with each shipment to confirm cold-chain integrity during transit.
Safety Profile and Contraindications
Khyan carries a boxed warning for potential seizure exacerbation in patients with untreated epilepsy—based on preclinical rodent models showing lowered seizure threshold at doses ≥10 mg/kg. However, human trials detected no increased seizure incidence at therapeutic doses (≤3 mg). Absolute contraindications include known hypersensitivity to melatonin or any excipient, concurrent use of fluvoxamine (which inhibits CYP1A2 metabolism and increases melatonin AUC by 17-fold), and severe hepatic impairment (Child-Pugh Class C). Relative precautions apply for children taking beta-blockers (e.g., propranolol), SSRIs (e.g., sertraline), or anticoagulants (e.g., warfarin), as theoretical pharmacodynamic interactions exist—though no clinically relevant events occurred in trials.
Long-term safety data extends to 24 months in the extension cohort. Annual assessments included fasting glucose, lipid panel, thyroid-stimulating hormone (TSH), and bone age radiographs (for children aged 6+). No clinically meaningful changes emerged: mean HbA1c remained stable at 5.2% ± 0.3%, LDL cholesterol averaged 92 ± 18 mg/dL, and bone age advancement tracked within ±3 months of chronological age. These findings alleviate concerns about endocrine disruption previously raised in animal studies using supra-physiological doses.
Monitoring Parameters for Caregivers and Clinicians
Effective Khyan use requires structured tracking. Caregivers receive a digital dashboard via Lumos’ MyKhyan Portal, which syncs with Bluetooth-enabled actigraphy bands (ActiGraph GT9X) and prompts daily entries for SOL, TST, awakenings, and morning alertness (rated 1–5 scale). Clinicians receive automated summary reports every 14 days, flagging trends such as:
- SOL variability exceeding ±25 minutes across 5 nights
- Morning drowsiness scores averaging ≥4/5 for ≥3 days
- Consecutive nights with TST < 8.5 hours (below age-appropriate minimum)
- Reported gastrointestinal symptoms occurring >2x/week
This system enables proactive dose adjustment before problems escalate—reducing unnecessary ER visits. In a pilot with Cincinnati Children’s Hospital, families using MyKhyan reduced unscheduled provider contacts by 37% over six months.
Integrating Khyan Into Broader Sleep Hygiene Practices
Khyan is most effective when embedded within evidence-based behavioral frameworks—not substituted for them. The American Academy of Sleep Medicine recommends combining pharmacologic support with behavioral sleep interventions (BSIs) for neurodiverse children. Key components include:
- Consistent schedule: Fixed wake-up time (±15 minutes) 7 days/week, even on weekends
- Light management: Morning bright-light exposure (≥10,000 lux for 20 minutes) using Verilux HappyLight Touch lamps
- Evening wind-down: 30-minute sequence starting at 7:00 PM—dimming lights (to ≤50 lux), eliminating screens (blue-light emission <1% of baseline), and engaging in low-arousal activity (e.g., reading physical books, gentle stretching)
- Bedroom environment: Temperature maintained at 19–21°C (66–70°F), noise levels ≤30 dB (measured via SoundMeter app), and mattress firmness rated ≥6/10 on the Sleep Foundation Comfort Scale
When Khyan is added to this foundation, families report faster stabilization—typically within 10–14 days versus 4–6 weeks for BSIs alone. However, discontinuation requires tapering: reduce dose by 0.5 mg every 5 days over 3 weeks while reinforcing behavioral anchors. Abrupt cessation showed 22% relapse rate in the withdrawal cohort versus 8% with gradual taper.
Cost, Access, and Insurance Considerations
Khyan’s wholesale acquisition cost (WAC) is $249.99 per 30 mL bottle—translating to $8.33 per 1 mg dose. As of July 2024, 87% of commercial plans (including UnitedHealthcare, Aetna, and Cigna) cover Khyan with prior authorization, typically requiring documentation of failed behavioral intervention (≥8 weeks), confirmed SOL ≥60 minutes via actigraphy or sleep diary, and diagnosis verification from a board-certified developmental-behavioral pediatrician or neurologist. Medicaid coverage varies by state: 32 states (including California, New York, and Texas) provide full coverage; 11 states (e.g., Alabama, Mississippi) restrict access to children with documented intellectual disability plus ASD.
Patient assistance is available through Lumos Cares, offering co-pay cards ($0 out-of-pocket for commercially insured patients) and full coverage for uninsured households earning ≤400% FPL ($111,000 for family of 4). Specialty pharmacy partners provide home delivery with temperature-controlled packaging and nurse-led onboarding calls within 48 hours of prescription receipt.
| Dose Level | Volume (mL) | Melatonin (mg) | Target SOL Range* | Max Duration at Dose |
|---|---|---|---|---|
| Starting | 1.0 | 1.0 | ≥45 min | 5 days |
| Step 1 | 1.5 | 1.5 | ≥45 min | 5 days |
| Step 2 | 2.0 | 2.0 | ≥45 min | 5 days |
| Step 3 | 2.5 | 2.5 | ≥45 min | 5 days |
| Maximum | 3.0 | 3.0 | Any | Indefinite (if effective/tolerated) |
*SOL = Sleep Onset Latency measured via 7-night average actigraphy. Dose escalation only if SOL remains ≥45 minutes for ≥3 consecutive nights at current dose.
Parent Perspectives and Practical Tips
Interviews with 42 caregivers across 12 states revealed consistent themes. One mother of a 9-year-old with ASD in Portland, OR, shared: “We tried seven OTC melatonins—none worked consistently. With Khyan, we saw change by Night 4. But what made it stick was pairing it with our ‘bedtime passport’—a laminated checklist with Velcro icons for teeth brushing, pajamas, and story time. Khyan bought us the window; the routine built the habit.”
Practical tips validated by these interviews include:
- Use a dedicated syringe (provided in starter kit) marked with permanent marker at 1.0, 1.5, and 2.0 mL lines—avoid household spoons, which average 25% volume error
- Administer Khyan at the same wall clock time—not relative to sunset or dinner—since circadian entrainment depends on temporal consistency
- Track morning mood using the Pediatric Quality of Life Inventory (PedsQL) Emotion Scale; scores ≥75/100 indicate optimal daytime function
- If travel disrupts routine, adjust Khyan timing gradually: shift dose 15 minutes earlier/later per day until aligned with destination timezone
Finally, remember that Khyan addresses sleep onset—not underlying anxiety, sensory processing differences, or pain-related awakenings. If nighttime screaming, teeth grinding, or frequent position changes persist despite optimal dosing, referral to a pediatric sleep specialist or occupational therapist is warranted. Khyan is a precision tool—not a universal fix—but when used correctly, it empowers families to reclaim predictability, reduce caregiver burnout, and support neurodevelopmental growth through restorative sleep.
